Peer-reviewed medical journal
Appears in 4 stories · Last updated Nov 4, 2026
Published the trial online in August 2026 and in its November 3, 2026 print issue
All 20,604 patients in the trial had low statin adherence: they filled their prescriptions less than 80% of the time in the prior year and had no refill in the prior three months. Kaiser Permanente sent them a secure portal message, a text, a nonsecure email, or nothing beyond usual communication, then counted who refilled.
Updated 7 days ago
Published the BPL-003 phase 2b trial
A single dose of mebufotenin benzoate nasal spray reduced depression scores for at least eight weeks in a 193-patient phase 2b trial published in the Journal of the American Medical Association. The psychedelic compound, found in Sonoran Desert toad venom, cut scores on the Montgomery-Åsberg Depression Rating Scale (MADRS) by 11.1 points at day 29 with a 12-milligram dose, versus 5.8 points for a 0.3-milligram comparator.
Updated Oct 28
As of October 2026: Published the patent portfolio analysis
The average FDA-approved drug now carries more than three times as many patents as it did in 1990. A JAMA study of 1,981 small-molecule drugs found the mean patent count per drug rose from 2.1 to 6.9 between 1990 and 2019.
Updated Oct 11
As of September 2026: Publisher of the trial results
About 23 million babies are born small for gestational age every year, smaller than expected for their weeks of pregnancy. They carry higher risks of stunting, developmental delay, and death in early childhood. A Delhi trial asked whether early help could change that.
Updated Sep 22
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
